6th Genotoxic Impurities Summit: Nitrosamines & Beyond 2026

Genotoxic Impurities Nitrosamines & Beyond
Event Details

Conference Overview

Join industry leaders, regulatory experts and scientific innovators at the 6th Genotoxic Impurities: Nitrosamines & Beyond Summit. This premier two-day virtual event is dedicated to the latest developments, regulatory expectations and technical challenges in global impurity control.

Day 1 establishes the strategic framework for risk assessment. It features expert-led sessions on 2026 regulatory updates from the FDA and EMA, the qualification of drug substances and integrated in silico modeling. Discussions will highlight the newest structural risks, including the February 2026 Lhasa data-sharing initiative, CPCA potency categories and the ICH M7 purge factor strategy.

Day 2 focuses on the practical execution of testing and manufacturing. Sessions cover advanced trace-level analytical validation, high-sensitivity detection at ppb levels and formulation-based mitigation. Attendees will explore unique challenges in biologics, packaging leachables and cross-contamination risks, concluding with best practices for lifecycle management and post-approval change control.

We Will Talk About

2026 Regulatory & Strategy
Key takeaways from EMA’s early 2026 Appendix 1 and the integration of nitrosamine oversight into routine inspection frameworks.
Establishing safety-based limits and utilizing ICH M7 purge factors to justify reduced batch testing.

Predictive Risk & Data Sharing
Using integrated in silico modeling (Derek/Sarah Nexus) and amine precursor mapping to identify DNA-reactive groups early.
Applying updated insights from the Lhasa initiative and CPCA frameworks to categorize complex NDSRIs.

Analytical Precision & Validation
High-resolution LC-MS/MS and GC-MS strategies capable of quantifying impurities at the parts-per-billion (ppb) level.
Validating trace-level methods to ensure specificity and accuracy for 2026-2027 audit standards.

Manufacturing & Lifecycle Controls
Mitigation through smart formulations, packaging E&L screening and managing cross-contamination from cleaning pitfalls or NOx levels.
Addressing unique risks in Biologics and maintaining compliance during post-approval site transfers and supplier changes.

Who Is It For?

The event covers key areas of product quality, regulatory compliance and manufacturing processes. The following departments would benefit from the insights shared at the conference:

● Regulatory Affairs Professionals
● Analytical Scientists and Chemists
● Toxicologists and Safety Assessors
● CMC and QA/QC Experts
● Computational Toxicology Specialists
● Good Manufacturing Practice (GMP)
● Biologics and Device Developers
● Process Development Scientists
● Risk Assessment
● Packaging
● Analytical Development
● Regulatory Affairs

Agenda 6th GTI Summit: Nitrosamines & Beyond 2026

Download the full summit program to find speaker biographies, case studies, key takeaways, the day's schedule, and details of each session.

Speaking Companies

Previous Events
Genotoxic Impurities Nitrosamines
December 4, 2025
Two-day virtual event focused on the latest developments, technical challenges in genotoxic impurity control. [Recording: 14 video sessions].
Expired
[•REC] - €495
Genotoxic-Impurities-Nitrosamines-Beyond
December 4, 2024
Meeting with subject matter experts to evaluate different points of view on how to solve the problems associated with mutagenic impurities. [Recording: 13 video sessions].
Expired
[•REC] - €295

Speaker Board
Crystal DSilva
Associate Director – Preclinical Toxicology
Baxter
George Johnson
Associate Professor
Swansea University
Andrew Teasdale
Former Head of Impurity Management & CMC Strategy
AstraZeneca
Raphael Nudelman
Chemical Toxicologist
Nudelman ChemTox Consulting

Summit Agenda

◆  Thematic Focus: Both Nitrosamines & General Mutagenic Impurities.

◆  Description: Reviewing early 2026 EMA Appendix 1 additions and how FDA and EMA are integrating nitrosamine oversight into routine, standard inspection frameworks.

◆  Thematic Focus: Both Nitrosamines & General Mutagenic Impurities

◆  Description: Establishing safety-based limits and navigating the transition from ICH Q3A/B to mutagenic thresholds for stability-related impurities.

◆  Thematic Focus: Both Nitrosamines & General Mutagenic Impurities.

◆  Description: Using virtual tools (Derek/Sarah Nexus) to identify DNA-reactive groups and chemical mapping to predict if precursors are prone to nitrosation.

◆  Thematic Focus: Nitrosamines & NDSRIs.

◆  Description: Utilizing February 2026 Lhasa data-sharing initiative to speed up safety profiles and categorize NDSRIs.

◆  Thematic Focus: Nitrosamines & NDSRIs.

◆  Description: A practical walkthrough of the assessment process focusing on evaluating complex NDSRIs within multi-ingredient pharmaceutical formulations.

◆  Thematic Focus: Nitrosamines & NDSRIs.

◆  Description: Step-by-step guidance on using the CPCA framework for complex nitrosamines and interpreting data from the Enhanced Ames Test (EAT).

◆  Thematic Focus: General Mutagenic Impurities.

◆  Description: Using the ICH M7 framework to prove that manufacturing processes naturally eliminate impurities justifying the reduction of routine batch testing.

◆  Focus: Nitrosamines & NDSRIs.

◆  Description: Advanced LC-MS/MS and GC-MS strategies to quantify trace impurities while eliminating sample-prep artifacts.

◆  Focus: Both Nitrosamines & General Mutagenic Impurities.

◆  Description: Key requirements for validating trace-level methods. Ensuring specificity and accuracy at the Limit of Quantitation (LoQ) to satisfy 2026-2027 audit standards.

◆  Focus: Nitrosamines & NDSRIs.

◆  Description: Practical mitigation using nitrite scavengers and pH modifiers to block nitrosation in finished dosage forms.

◆  Focus: Both Nitrosamines & General Mutagenic Impurities.

◆  Description: E&L screening for primary packaging and single-use processing tools used in modern manufacturing.

◆  Focus: General Mutagenic Impurities.

◆  Description: Assessing genotoxic risks in large molecules and peptides originating from synthetic reagents and single-use manufacturing equipment.

◆  Focus: Both Nitrosamines & General Mutagenic Impurities.

◆  Description: Preventing cross-contamination in shared facilities and managing environmental factors like air quality (NOx) during production.

◆  Focus: Both Nitrosamines & General Mutagenic Impurities.

◆  Description: Managing impurity risks during site transfers, supplier changes and scale-up to ensure continuous compliance throughout the product lifecycle.

Registration Tickets

🔥 50% OFF | JUST €295 – LIMITED TIME ONLY. The discount is valid until 15th of June 2026

Email us at info@uventia.com or submit a REQUEST BROCHURE.

most popular
2 Days Ticket + Recording
Original price was: €595.Current price is: €295.

Full access to the 2 days online event.

Recording of 2 days event sessions.

Digital certificate of attendance.

List of participants.

PDF presentations.

1 Day Ticket + Recording
415

Full access to the 1 day online event.

Recording of 1 day event sessions.

Digital certificate of attendance.

List of participants.

PDF presentations.

2 Days Recording
495

Recording of 2 days event sessions.

Digital certificate of attendance.

List of participants.

PDF presentations.

To register to the summit as a Delegate, complete the registration form. After submission, you will receive confirmation and invoice. Registration for the virtual event covers access to all online material in the Proceedings including keynotes, PDF presentations and papers, posters, and delegate list with contacts as well as video recordings of speakers' speeches.

If you need more information, please contact us at info@uventia.com

Event Details